Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

Gascón Cánovas, Juan José; Gómez Espín, Rosa; Nicolás de Prado, Isabel; Rentero Redondo, Lorena; Urbieta Sanz, Elena; Iniesta Navalón, Carles.
Rev. esp. enferm. dig ; 112(8): 590-597, ago. 2020. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-199962

Documentos relacionados

  1. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
  2. Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
  3. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
  4. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
  5. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
  6. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
  7. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
  8. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
  9. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
  10. Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.